Mycophenolate mofetil:
Mycophenolic acid:
Contraindicated in:
Use Cautiously in:
CV: edema, hypertension, hypotension, tachycardia.
Derm: rash.
Endo: hyperglycemia.
F and E: hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia.
GI: anorexia, constipation, diarrhea, nausea, vomiting, abdominal pain, GI BLEEDING.
GU: renal impairment.
Hemat: leukocytosis, leukopenia, thrombocytopenia, anemia, pure red cell aplasia.
Metab: hypercholesterolemia.
Neuro: anxiety, confusion, dizziness, headache, insomnia, paresthesia, sedation, tremor, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML).
Misc: fever, infection (including activation of latent viral infections such as Polyomavirus-associated nephropathy or Hepatitis B/C), acute inflammatory syndrome, MALIGNANCY.
Drug-Drug:
(Generic available)
Mycophenolate Mofetil
Mycophenolic Acid
Mycophenolate Mofetil
Kidney Transplantation
24 hr after transplantation and switched to PO as soon as possible (IV not recommended for
14 days).
3 mo): 600 mg/m2 twice daily (not to exceed 2 g/day).
24 hr after transplantation and switched to PO as soon as possible (IV not recommended for
14 days).
3 mo): 600 mg/m2 twice daily; if well tolerated, can ↑ to 900 mg/m2 twice daily (not to exceed 3 g/day).
24 hr after transplantation and switched to PO as soon as possible (IV not recommended for
14 days).
3 mo): 600 mg/m2 twice daily; if well tolerated, can ↑ to 900 mg/m2 twice daily (not to exceed 3 g/day).Renal Impairment
Mycophenolic Acid
Mycophenolate mofetil and mycophenolic acid should not be used interchangeably without the advice of a health care professional.
Kidney Transplantation
1.19 m2): 400450 mg/m2 twice daily (not to exceed 720 mg twice daily).Absorption: Following oral and IV administration, mycophenolate mofetil is rapidly hydrolyzed to mycophenolic acid (MPA), the active metabolite. Absorption of enteric-coated mycophenolic acid (Myfortic) is delayed compared with mycophenolate mofetil (CellCept).
Distribution: Cross the placenta and enter breast milk.
Protein Binding: MPA: 97%.
Metabolism/Excretion: MPA is extensively metabolized; <1% excreted unchanged in urine. Some enterohepatic recirculation of MPA occurs.
Half-life: MPA: 818 hr.
(blood levels of MPA)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| mycophenolate mofetil-PO | rapid | 0.251.25 hr | N/A |
| mycophenolic acid | rapid | 1.52.75 hr | N/A |
100.5°F, cold symptoms [runny nose, sore throat], flu symptoms [upset stomach, stomach pain, vomiting, diarrhea], earache or headache, pain during urination, frequent urination, white patches in mouth or throat, unexpected bruising or bleeding, cuts, scrapes, or incisions that are red, warm, and oozing pus) or PML.NDC Code*